Sanofi to Cut 900 Jobs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sanofi to Cut 900 Jobs



Sanofi is planning to shed approximately 900 jobs in France in the lead up to 2015 as it seeks to implement certain key strategic objectives.

In a press statement, Sanofi explained that reduction measures could involve early retirements, mobility proposals and repositioning within France. No relocation of sites or any changes to the number of industrial sites is planned in France; however, the company also added that the function of its Toulouse site “remains to be specified”. Over the summer, the company identified potential stakeholders who could maintain the site’s scientific or technological capacity and a working group will be established shortly to explore all available options. The company hopes to have a firm solution for the site within the coming months.

The workforce reduction is being undertaken to achieve three strategic objectives that the company first revealed at the beginning of July 2012. Sanofi is seeking to improve the momentum and success of research activities; improve the economic performance of Sanofi Pasteur’s industrial units; and streamline support functions.

In the led up to 2015, Sanofi intends for its R&D activities in France to evolve to strengthen the company’s scientific, academic and private network. Plans include progressively adapting the Montpellier site into a strategic centre focused on development, and increasing research activities in Vitry/Alfortville and Chilly-Mazarin/Longjumeau. In addition, Sanofi intends to create a global center of excellence in infectious diseases in Lyon.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
11%
To select process for new products only
25%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here